Pertussis vaccine - ILiAD/INSERM

Drug Profile

Pertussis vaccine - ILiAD/INSERM

Alternative Names: BPZE 1

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator INSERM; Institut Pasteur
  • Developer ILiAD Biotechnologies; INSERM; Institut Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Pertussis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pertussis in France (Intranasal)
  • 02 Jun 2015 INSERM plans a phase Ib trial for Pertussis in Sweden (NCT02453048)
  • 21 Jan 2014 Phase-I clinical trials in Pertussis (In volunteers) in Sweden (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top